By Deena Beasley Oct 29 (Reuters) - Bristol Myers Squibb raised its full-year revenue forecast on Thursday, citing strong sales of its newer medicines, but lowered its 2026 earnings per share projection due to a hefty acquisition-related charge. The U...
(Teleborsa) - Bristol Myers Squibb, an American biopharmaceutical giant, closed the third quarter of 2026 with revenues of 13.1 billion dollars, up 7% compared to 12.2 billion dollars...